hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06323642, orgStudyIdInfo id: F.1-1/20ERB/SZABMU/941, briefTitle: Role of Probiotics as Adjunct Therapy Along With Standard Care in Decreasing Hospital Stay and Improving Symptoms in Pediatric Patients Admitted With Severe Pneumonia, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-09-01, primaryCompletionDateStruct date: 2024-03-31, completionDateStruct date: 2024-03-31, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: Shaheed Zulfiqar Ali Bhutto Medical University, class: OTHER, descriptionModule briefSummary: Probiotics as adjuvant therapy along with standard care can decrease hospital stay and improve symptoms (fever, tachypnea,cough) in pediatric patients admitted with severe pneumonia., conditionsModule conditions: Pneumonia, conditions: Probiotics, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: randomized control trial, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, maskingDescription: The patients and their parents/attendants will be kept blind to the fact that they are receiving either probiotic or placebo, whoMasked: PARTICIPANT, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: probiotic containing Lactobacillus rhamnosus GG., interventions name: placebo, outcomesModule primaryOutcomes measure: Number of days in hospital, secondaryOutcomes measure: Number of days with cough, fever, eligibilityModule sex: ALL, minimumAge: 6 Months, maximumAge: 2 Years, stdAges: CHILD, contactsLocationsModule locations facility: Pakistan Institute of Medical Sciences, status: RECRUITING, city: Islamabad, state: Punjab, zip: 12000, country: Pakistan, contacts name: Nighat Haider, FCPS, role: CONTACT, phone: 03212125768, email: nighathaider@hotmail.com, contacts name: rashiqa saadat, MBBS, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 33.72148, lon: 73.04329, hasResults: False
protocolSection identificationModule nctId: NCT06323629, orgStudyIdInfo id: STUDY006201, briefTitle: Effects of Recursive Self-feedback on Speech Production in Aphasia, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-03, completionDateStruct date: 2025-03, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: University of South Florida, class: OTHER, collaborators name: Center for Smart Use of Technologies to Assess Real-world Outcomes, descriptionModule briefSummary: The goal of this clinical trial is to test the effects of recursive self-feedback procedures on spontaneous speech production in stroke survivors with impaired speech production (aphasia). The main question it aims to answer is:• To what extent can stroke survivors with aphasia use their self-feedback alone to improve their spontaneous speech production?Participants will be engaged in the following activities:* They will perform language and cognitive tasks.* Afterwards, they will receive treatments using tablets and headphones at no cost to them.* The experimental treatments (recursive self-feedback procedures) entails responding to prompts, listening to playbacks of their speech response and attempt to minimize/correct the errors in the next attempt. This process will be repeated multiple times per prompt.* The experimental treatments are two: an adaptive version that adapts the complexity of the treatment prompt and a non-adaptive version that does not adapt task complexity.* Researchers will compare the experimental treatments to see if both have similar effects on improving spontaneous speech production., conditionsModule conditions: Aphasia, conditions: Stroke, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 45, type: ESTIMATED, armsInterventionsModule interventions name: Adaptive recursive self-feedback procedure, interventions name: Non-adaptive recursive self-feedback procedure, outcomesModule primaryOutcomes measure: Speaking rate, primaryOutcomes measure: Speech initiation latency in milliseconds, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06323603, orgStudyIdInfo id: 3-1, briefTitle: Biomonitoring of Occupationally Populations Exposed to Micro and Nanoplastic, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-06-30, primaryCompletionDateStruct date: 2024-06, completionDateStruct date: 2024-09, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: Ricard Marcos, class: OTHER, collaborators name: Finnish Institute of Occupational Health, descriptionModule briefSummary: The biomonitoring study aims to evaluate genotoxic damage and other parameters of exposure in different occupational exposed populations that work directly with different plastics., conditionsModule conditions: Occupational Exposure, conditions: Genotoxicity, conditions: Damage Dna, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 45, type: ESTIMATED, armsInterventionsModule interventions name: Micro and nanoplastic, outcomesModule primaryOutcomes measure: Characterization of macro and nanoplastics, primaryOutcomes measure: Genotoxic evaluation by the Micronucleus assay, primaryOutcomes measure: Genotoxic evaluation by the Comet assay, primaryOutcomes measure: Cytokine release, primaryOutcomes measure: Microbiota analysis from feces by MinIOn, secondaryOutcomes measure: Analyses of surrogate biomarkers, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Textile industry, status: COMPLETED, city: Helsinki, country: Finland, geoPoint lat: 60.16952, lon: 24.93545, locations facility: Recycling company, status: COMPLETED, city: Alicante, country: Spain, geoPoint lat: 38.34517, lon: -0.48149, locations facility: Textile Industry, status: COMPLETED, city: Alicante, country: Spain, geoPoint lat: 38.34517, lon: -0.48149, locations facility: Control recruitment, status: RECRUITING, city: Barcelona, country: Spain, contacts name: Susana Pastor, role: CONTACT, geoPoint lat: 41.38879, lon: 2.15899, hasResults: False
protocolSection identificationModule nctId: NCT06323590, orgStudyIdInfo id: UAB 2372, secondaryIdInfos id: UAB, type: OTHER, domain: UAB, briefTitle: Refining the Role of Mid-induction Bone Marrow Biopsy in Acute Myeloid Leukemia: A Pilot Study, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2028-05, completionDateStruct date: 2028-05, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: University of Alabama at Birmingham, class: OTHER, descriptionModule briefSummary: The purpose of the study is to observe the outcomes of patients with acute myeloid leukemia who do not receive an immediate second round of chemotherapy after undergoing a standard mid-induction bone marrow biopsy., conditionsModule conditions: Acute Myeloid Leukemia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: rates of complete remission, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Alabama at Birmingham, city: Birmingham, state: Alabama, zip: 35294, country: United States, contacts name: Omer Jamy, role: CONTACT, phone: 205-934-2721, email: omerjamy@uabmc.edu, contacts name: Omer Jamy, role: CONTACT, phone: 2059342721, email: omerjamy@uabmc.edu, contacts name: Omer Jamy, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 33.52066, lon: -86.80249, hasResults: False
protocolSection identificationModule nctId: NCT06323577, orgStudyIdInfo id: TUH rKA vs MA TKA, briefTitle: Comparing Efficacy Between Restricted Kinematic Alignment vs Mechanical Alignment in Bilateral TKA, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-14, primaryCompletionDateStruct date: 2026-05-31, completionDateStruct date: 2026-05-31, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: Thammasat University Hospital, class: OTHER, descriptionModule briefSummary: The goal of this RCT is to investigate efficacy between restricted kinematic alignment and mechanical alignment TKA in simultaneous bilateral TKA patients.The main question\[s\] it aims to answer are:* Does rKA have better functional outcomes than MA in simultaneous bilateral TKA patients?* Does rKA have lower pain score than MA in simultaneous bilateral TKA patients? Participants will undergo simultaneous bilateral TKA and randomized one side will use rKA and the other side will use MA., conditionsModule conditions: Osteoarthritis, Knee, conditions: TKA, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Restricted kinematic alignment, interventions name: Mechanical alignment, outcomesModule primaryOutcomes measure: Forgotten joint score, secondaryOutcomes measure: Modified WOMAC score, secondaryOutcomes measure: Range of motion, secondaryOutcomes measure: Pain score, secondaryOutcomes measure: Hip knee ankle angle, secondaryOutcomes measure: Complications, secondaryOutcomes measure: Incidence of soft tissue releasing, eligibilityModule sex: ALL, minimumAge: 40 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Thammasat University, status: RECRUITING, city: Khlong Luang, state: Pathum Thani, zip: 12120, country: Thailand, contacts name: Yot Tanariyakul, M.D., role: CONTACT, phone: 663930257, email: y.tanariyakul@gmail.com, contacts name: Nattapol Tammachote, M.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 14.06467, lon: 100.64578, hasResults: False
protocolSection identificationModule nctId: NCT06323564, orgStudyIdInfo id: 21C223, briefTitle: Exploring Emotional Intelligence and Cognitive Flexibility in Anorexia Nervosa and Parkinson's Disease., acronym: INTELLEGO, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-01-13, primaryCompletionDateStruct date: 2024-08-13, completionDateStruct date: 2025-01-13, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: Istituto Auxologico Italiano, class: OTHER, descriptionModule briefSummary: The main aim of this study is to demonstrate how disorders characterized by different types of "inflexibility", cognitive-affective type for Anorexia nervosa and motor one for Parkinson's disease, have an impact on how emotional stimuli are processed and on the transition within emotional states., conditionsModule conditions: Anorexia Nervosa, conditions: Parkinson Disease, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Neuropsychological tests in PD, interventions name: Self-report questionnaires in PD, interventions name: International Affective Picture System (IAPS), interventions name: Neuropsychological tests in AN, interventions name: Self-report questionnaires in AN, interventions name: Analysis of bio-humoral parameters, outcomesModule primaryOutcomes measure: Change in International Affective Picture System (IAPS), secondaryOutcomes measure: Change in self-report questionnaires - STAI, secondaryOutcomes measure: Change in self-report questionnaires - BDI, secondaryOutcomes measure: Change in Heart rate variability, secondaryOutcomes measure: Change in analysis of bio-humoral parameters, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Istituto Auxologico Italiano, status: RECRUITING, city: Oggebbio, zip: 28824, country: Italy, contacts name: Riccardo Cremascoli, MD, PhD, role: CONTACT, geoPoint lat: 45.99088, lon: 8.64663, hasResults: False
protocolSection identificationModule nctId: NCT06323551, orgStudyIdInfo id: 2023/50, briefTitle: The Effect of Mother's Smell and Breast Milk Smell on Pain, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-14, primaryCompletionDateStruct date: 2024-07-14, completionDateStruct date: 2024-12-24, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: Tarsus University, class: OTHER, descriptionModule briefSummary: The research was planned as a randomized controlled study to investigate the effect of breast milk smell and mother's smell applied while heel blood was taken to term babies in the Mersin City EAH Neonatal Intensive Care Unit between October and December 2023, on acute pain and crying duration. During the heel prick procedure, which is routinely performed in the neonatal intensive care unit, no pharmacological/non-pharmacological method will be applied to the control group to reduce the baby's pain before, during and after the heel prick. The baby's pain score will be evaluated by the observing nurse according to the NIPS pain scale 5 minutes before, during and 5 minutes after the procedure.In the study group that will be made to smell the mother's scent; The mother of each baby whose heel blood will be taken will be given a specially made cover made of 100% cotton yarn, sterilized the day before, and the mother will be asked to put the cover on her bare skin (on her bare skin) after the shower and to keep the cover on the mother's chest for one night (8 hours). It will be placed 15 cm away from the baby and smelled 5 minutes before and 5 minutes after the heel prick attempt. The baby's pain score will be evaluated by the observing nurse according to the NIPS pain scale 5 minutes before, during and 5 minutes after the procedure., conditionsModule conditions: Newborn; Vitality, conditions: Pain, conditions: Crying, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: randomized controlled, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 90, type: ESTIMATED, armsInterventionsModule interventions name: Mother's Smell, interventions name: Mother's Breast Milk Smell, outcomesModule primaryOutcomes measure: Neonatal Infant Pain Scale, secondaryOutcomes measure: criying time, eligibilityModule sex: ALL, minimumAge: 1 Day, maximumAge: 15 Days, stdAges: CHILD, contactsLocationsModule locations facility: Tarsus State Hospital, status: RECRUITING, city: Mersin, country: Turkey, contacts name: Atiye Karakul, Ass. Prof., role: CONTACT, phone: 90(324) 600 00 33, phoneExt: 2231, email: atiyekarakul@gmail.com, geoPoint lat: 36.79526, lon: 34.61792, hasResults: False
protocolSection identificationModule nctId: NCT06323512, orgStudyIdInfo id: Nanjing, briefTitle: Pulmonary Arteyr Denervation for Heart Failure, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2024-11-01, completionDateStruct date: 2025-12-30, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Nanjing First Hospital, Nanjing Medical University, class: OTHER, descriptionModule briefSummary: Prolonged pulmonary venous congestion culminates in pulmonary hypertension, defined as a mean pulmonary arterial pressure \> 20 mmHg and pulmonary artery wedge pressure \>15 mmHg at rest, as determined by right heart catheterization. Pulmonary hypertension secondary to heart failure (PH-HF) is further stratified into isolated post-capillary pulmonary hypertension (Ipc-PH, pulmonary vascular resistance (PVR) is ≤2 Woods Unit) and combined pre- and post-capillary pulmonary hypertension (Cpc-PH, PVR \> 2 Woods Unit), the later reflecting additional pulmonary vascular constriction or remodeling in addition to passive PH. While medications tailored for World Health Organization defined Group I pulmonary arterial hypertension are not endorsed for PH-HF according to current guidelines, the coexistence of pulmonary hypertension exacerbates the severity of heart failure. Given the presence of pulmonary arterial vasoconstrictor and heightened sympathetic nervous activity in patients with heart failure, the PADN-5 study has demonstrated the safety and efficacy of pulmonary artery denervation (PADN) for patients with CpcPH, characterized by the improvements in left ventricular ejection fraction, cardiac output, clinical outcome, and reductions in left atrial pressure, pulmonary arterial pressure, and PVR. Our objective is to assess the feasibility, safety, and efficacy of PADN for patients with heart failure independent of left ventricular ejection fraction (HFrEF or HFpEF) without pulmonary hypertension (N=30, 15 with HFrEF and another 15 with HFpEF)., conditionsModule conditions: Heart Failure, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Pulmonary artery denervation (PADN), outcomesModule primaryOutcomes measure: Left ventricular ejection fraction, primaryOutcomes measure: Tricuspid annuls peak systolic excursion (TAPSE), primaryOutcomes measure: 6 minute walk distance changes, secondaryOutcomes measure: All-cause death, secondaryOutcomes measure: Rehospitalization, secondaryOutcomes measure: NT-proBNP, secondaryOutcomes measure: Superoxide dismutase (SOD) 3, secondaryOutcomes measure: Plasma noradrenaline, otherOutcomes measure: All outcomes will be stratified by HFrEF and HFpEF, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06323473, orgStudyIdInfo id: Maitake001, briefTitle: Maitake for Integrative Cancer Care, acronym: Maitake, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07-01, primaryCompletionDateStruct date: 2025-08-01, completionDateStruct date: 2025-09-01, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: The Canadian College of Naturopathic Medicine, class: OTHER, descriptionModule briefSummary: Maitake is an edible mushroom that is used for both its nutritional and medicinal properties. Human and animal studies have shown Maitake may help improve immune function; however, its effectiveness in people with cancer is not clear. The investigators aim to measure if Maitake has any immunomodulatory effects when given alongside conventional systemic cancer therapy., conditionsModule conditions: Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Uncontrolled single arm clinical trial, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Black Maitake Prothera, outcomesModule primaryOutcomes measure: Changes in absolute neutrophil count, secondaryOutcomes measure: Incidence of febrile neutropenia, secondaryOutcomes measure: Change in neutrophil to lymphocyte ratio (NLR), secondaryOutcomes measure: Change in platelet to lymphocyte ratio (PLR), secondaryOutcomes measure: Change in high-sensitivity C-reactive protein (CRP), secondaryOutcomes measure: Changes in Quality of Life, secondaryOutcomes measure: Changes in hemoglobin A1c (HbA1c), secondaryOutcomes measure: Incidence of adverse events, secondaryOutcomes measure: Incidence of dose reductions or delays in systemic therapy, secondaryOutcomes measure: Addition of new medications to combat neutropenia, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The Centre for Health Innovation, city: Ottawa, state: Ontario, zip: K2P 0M7, country: Canada, contacts name: Mark Legacy, role: CONTACT, phone: 613-792-1222, phoneExt: 1, email: mlegacy@thechi.ca, geoPoint lat: 45.41117, lon: -75.69812, locations facility: Canadian College of Naturopathic Medicine - Integrative Cancer Centre, city: Toronto, state: Ontario, zip: M2K 1E2, country: Canada, contacts name: Daniel Lander, role: CONTACT, phone: 416-498-1255, phoneExt: 280, email: dlander@ccnm.edu, geoPoint lat: 43.70011, lon: -79.4163, hasResults: False